Oxo Chemie completes Phase III enrollment

Oxo Chemie completed enrollment of 240 HIV patients with <=50 CD4 T cells/mm3 in a placebo-controlled North American Phase III trial of its Macrokine ( WF10) tetrachlorodecaoxygen chlorite compound to...